B3 Therapeutics is developing a novel approach to treat brain tumors using sustained-release, nanoparticle(NP)-encapsulated drugs that are delivered into the CNS via direct CSF administration. With this approach, we can deliver cancer drugs directly to the tumor environment and limit systemic exposure to expand the therapeutic index and significantly prolong survival (and potentially achieve complete remission) to patients in urgent need of novel therapies. Our approach is compatible with a breadth of therapeutic agents and can be applied to a diverse range of primary CNS tumors, metastases in the brain and spine, and other CNS indications beyond cancer. The founders include seasoned biotech entrepreneurs, world-class physicians and scientists with experience translating work from bench-to-beside. Blavatnik funding will enable further de-risking and development of B3NPs, including safety/tox of lead NP, evaluation of additional compounds, and optimization of additional NP formulations.